These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

27 related articles for article (PubMed ID: 16900112)

  • 1. New clot busters threaten Genentech's tPA.
    Davidson S
    Nat Biotechnol; 1997 May; 15(5):405. PubMed ID: 9131608
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices.
    Moll S; Kenyon P; Bertoli L; De Maio J; Homesley H; Deitcher SR
    J Clin Oncol; 2006 Jul; 24(19):3056-60. PubMed ID: 16809729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug evaluation: alfimeprase, a plasminogen-independent thrombolytic.
    Shah AR; Scher L
    IDrugs; 2007 May; 10(5):329-35. PubMed ID: 17487785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishing an alteplase dosing protocol for hemodialysis-catheter thrombosis.
    Nguyen TV; Dikun M
    Am J Health Syst Pharm; 2004 Sep; 61(18):1922-4. PubMed ID: 15487882
    [No Abstract]   [Full Text] [Related]  

  • 5. Genentech's heart drug.
    Ezzell C
    Nature; 1989 Mar; 338(6210):6. PubMed ID: 2493137
    [No Abstract]   [Full Text] [Related]  

  • 6. Alfimeprase to succeed Genentech's alteplase?
    Vastag B
    Nat Biotechnol; 2006 Aug; 24(8):875-6. PubMed ID: 16900112
    [No Abstract]   [Full Text] [Related]  

  • 7. Alfimeprase: a novel recombinant direct-acting fibrinolytic.
    Deitcher SR; Funk WD; Buchanan J; Liu S; Levy MD; Toombs CF
    Expert Opin Biol Ther; 2006 Dec; 6(12):1361-9. PubMed ID: 17223743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombolytic therapy with alteplase for ischaemic stroke.
    Drug Ther Bull; 2009 Feb; 47(2):14-8. PubMed ID: 19193701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alteplase for the management of occluded central venous access devices: safety considerations.
    Smith LH
    Clin J Oncol Nurs; 2008 Feb; 12(1):155-7. PubMed ID: 18258586
    [No Abstract]   [Full Text] [Related]  

  • 10. Fibrolase: trials and tribulations.
    Markland FS; Swenson S
    Toxins (Basel); 2010 Apr; 2(4):793-808. PubMed ID: 22069611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombolytic therapy for deep vein thrombosis: potential application of plasmin.
    Marder VJ
    Thromb Res; 2009; 123 Suppl 4():S56-61. PubMed ID: 19303506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of tissue plasminogen activator, ischemic stroke, and potential legal issues.
    Liang BA; Lew R; Zivin JA
    Arch Neurol; 2008 Nov; 65(11):1429-33. PubMed ID: 19001160
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.